Navigation Links
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Date:6/2/2009

nt of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates: R7128, a nucleoside analog for chronic HCV infections, has initiated a Phase 2b clinical trial in combination with Pegasys plus Copegus through a strategic collaboration with Roche; PSI-7851, an unpartnered, next generation HCV nucleotide analog, which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV that has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
2. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
3. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
4. Pharmasset Reports Fiscal Year End 2008 Financial Results
5. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
6. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
7. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
8. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
9. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... Ariz. , July 1, 2015 Prismic ... drugs and FDA-regulated medical foods, today announced the election ... A. Simonetti to its Board of Directors. ... Board members, Peter Moriarty , Chairman and CEO ... Krivulka and Martin Simonetti have accepted ...
(Date:7/1/2015)... , July 1, 2015  Imprimis Pharmaceuticals, ... focused on the development and commercialization of proprietary ... will ring The Nasdaq stock market closing bell ... the growing success of its Go Dropless™ campaign ... million cataract procedures are performed annually in the ...
(Date:7/1/2015)... GAITHERSBURG, Md. , July 1, 2015 ... live biotherapeutics and probiotic treatments, announced today that it ... Canada Natural and Non-prescription Health Products Directorate (NNHPD) to ... Visbiome was developed by Professor Claudio ... subject of extensive clinical investigation. Professor De Simone recently ...
Breaking Medicine Technology:Joseph Krivulka and Martin Simonetti Join Board of Prismic Pharmaceuticals 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 2Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 3Imprimis Pharmaceuticals to Ring The Nasdaq Stock Market Closing Bell 4ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3
... , , , INDIANAPOLIS, Dec. 9 ... leading provider of managed voice, Internet and data networking solutions ... that Indiana Blood Center has selected the company to provide ... 11 locations located throughout Indiana. Indiana Blood Center will also ...
... , , ... HBP; OTCQX: HXBPF) reports that at its Annual General Meeting ... Board of Directors , All seven Board members were ... of: , ,Donald H. Segal, Chairman of the Board and ...
Cached Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2Helix BioPharma Reports On 2009 Annual General Meeting 2Helix BioPharma Reports On 2009 Annual General Meeting 3
(Date:7/1/2015)... , ... - (PRWEB) July 01, 2015 , ... Lisa ... nationwide virtual 5K on August 15-16th (MSG Keys’ birthday) in memory of her late ... highly decorated soldier and recipient of the Bronze Star Medal, died during a Special ...
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is a proud ... paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority Setting Partnership put ... ten list they hope will guide future mesothelioma research. Surviving Mesothelioma has just ... , More than 450 mesothelioma patients, caregivers, and healthcare professionals answer ...
(Date:7/1/2015)... ... July 01, 2015 , ... B. E. Smith, ... retained to lead a national chief executive officer recruitment for Citizens ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/1/2015)... ... July 01, 2015 , ... METTLER TOLEDO is pleased ... weighing pans, ML-T balances give operators the room they need to carry out ... estate makes ML-T balances a perfect choice for day-to-day weighing in nearly any ...
Breaking Medicine News(10 mins):Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 2Health News:Citizens Medical Center Retains B. E. Smith to Recruit New CEO 3Health News:METTLER TOLEDO Launches Compact ML-T Balances: Larger Pan Offers Greater Weighing Flexibility in Tight Spaces 2
... A new drug cocktail might be the right mix ... standard therapy. Details of a new study supporting this ... treatments to work again. The findings were presented today ... The study involves post-menopausal women whose advanced breast cancers ...
... media are invited to attend a press availability period at ... scientific meeting evaluating the safety of soy infant formula. An ... research on soy infant formula to determine whether exposure to ... expert panel will also indentify data gaps and research needs. ...
... Technique might work with many other viruses, researchers say ... they,ve shown that human stem cells can be turned ... virus that causes AIDS. , Potentially, they say, the ... demonstrated in this proof-of-principle study that this type of ...
... vaccines, safety monitoring and improved federal coordination , ... better coordination are needed to develop vaccines for serious ... U.S. report says. , The report, from the Institute ... Plan. It cites a need to speed up development ...
... , PHILADELPHIA, Dec. 11 The Visiting ... home health and specialty services to patients who reside in ... offer include rehabilitative therapies, mental health services, wound and ostomy ... and social workers will provide these services to patients in ...
... , , , WINSTON-SALEM, N.C., Dec. 11 ... officers once again put the spotlight on mass murder in ... killings at Fort Hood, the Washington case raised questions about ... rampage. , Andrew Smiler, an assistant professor of psychology at ...
Cached Medicine News:Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Scientific panel evaluates soy infant formula safety 2Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2Health News:Mass Murderers: Why Do They Kill? 2
Straight shafts with 1 x 2 teeth. Serrated handle with polished finish. Delicate teeth....
Straight shafts with 0.12 mm teeth and 5 mm tying platform. Serrated handle with polished finish. Manufactured in titanium....
Angled 45 degree shafts with 0.5 teeth and 6 mm tying platform. Polished finish....
Angled 45 degree shafts 8 mm long with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Medicine Products: